Stockscreener 앱 받기
7.38
2.22%
0.16
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Barclays PLC Raises Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Where are the Opportunities in (IOVA) - Stock Traders Daily
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Insiders' US$48.3m Investments In Red Following Iovance Biotherapeutics' US$402m Dip In Market Value - Simply Wall St
KEI Comments on NIH Exclusive License to Iovance for T-cell Vaccine for Cancer Treatment - Knowledge Ecology International
Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Significant Increase in Short Interest - MarketBeat
State Street Corp Grows Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics' SWOT analysis: promising TIL therapy stock faces growth hurdles - Investing.com India
Interesting IOVA Call Options For January 2025 - Nasdaq
Prediction: This Stock Will Beat the Market in 2025 - Yahoo Finance
BNP Paribas Financial Markets Trims Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics: Steady Progress (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Charles Schwab Investment Management Inc. Has $17.96 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates - MSN
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63% - Yahoo Finance
Braidwell LP Has $2.05 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
(IOVA) On The My Stocks Page - Stock Traders Daily
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect - MSN
Intech Investment Management LLC Makes New $920,000 Investment in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
IOVAIovance Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Is Iovance Biotherapeutics Stock a Millionaire Maker? - MSN
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - GlobeNewswire
Iovance Biotherapeutics (STU:2LB) Operating Cash Flow per S - GuruFocus.com
Iovance Biotherapeutics (NASDAQ:IOVA) delivers shareholders favorable 68% return over 1 year, surging 10.0% in the last week alone - Simply Wall St
IOVA (Iovance Biotherapeutics) Total Assets : $991.12 Mil (As of Sep. 2024) - GuruFocus.com
Victory Capital Management Inc. Buys 115,387 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
IOVA (Iovance Biotherapeutics) Cash Flow from Financing : $389.32 Mil (TTM As of Sep. 2024) - GuruFocus.com
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back - MSN
Landscape Capital Management L.L.C. Takes $615,000 Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Eagle Asset Management Inc. Lowers Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
2 Innovative Stocks That Could Deliver Outsize Returns - Yahoo Finance
Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
Iovance Biotherapeutics (STU:2LB) Shares Outstanding (EOP) : 304.62 Mil (As of Sep. 2024) - GuruFocus.com
Long Term Trading Analysis for (IOVA) - Stock Traders Daily
Perceptive Advisors LLC's Strategic Acquisition in Iovance Bioth - GuruFocus.com
Iovance Biotherapeutics director Maynard sells $503k in stock - Investing.com
IOVA (Iovance Biotherapeutics) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Principal Financial Group Inc. - MarketBeat
Iovance Biotherapeutics Q3: A Beat, But A SelloffNow A Buy Opportunity - Seeking Alpha
HC Wainwright Has Positive Outlook for IOVA FY2027 Earnings - MarketBeat
2.88%
2.65%
자본화:
|
볼륨(24시간):